Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Christopher J. Forlenza, David Hoogstra, Donald Barkauskas, Lauren Saguilig, Suzanne D. Turner, Nina Prokoph, Perla Pucci, Lucy Hare, Leila Jahangiri, Rui Wu, Kojo S.J. Elenitoba-Johnson, Eric J. Lowe, Megan S. Lim

Blood (2024) 144 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2024-201677

Published: 2024

Journal Articles

Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes

Joshua D Brandstadter, Mechthild Lutge, Megan S Lim, Adam Bagg, Ira D. Miller, Michael V. Gonzalez, Bridget Austin, Salvatore F. Priore, Burkhard Ludewig, David C. Fajgenbaum, Ivan Maillard

Blood (2024) 144 (Supplement 1): 1155.

https://doi.org/10.1182/blood-2024-211070

Published: 2024

Journal Articles

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Criswell L. M. Lavery, Adam Bagg, Mary Jo Lechowicz, Daisy V. Alapat, Amy Chadburn, Megan S Lim, Gordan Srkalovic, Frits van Rhee, Joshua D Brandstadter, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 1156.

https://doi.org/10.1182/blood-2024-211190

Published: 2024

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy

Nikita Dave, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim, Daniel J. Landsburg

Blood (2022) 140 (Supplement 1): 6702–6703.

https://doi.org/10.1182/blood-2022-165073

Published: 2022

Journal Articles

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Daisy Alapat, Adam Bagg, Joshua D Brandstadter, Mary Jo Lechowicz, Hongzhe Lee, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 6520–6521.

https://doi.org/10.1182/blood-2022-170102

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma

Daniel J. Landsburg, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim

Blood (2022) 140 (Supplement 1): 6653–6655.

https://doi.org/10.1182/blood-2022-165056

Published: 2022

Journal Articles

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Daisy Alapat, Adam Bagg, Mary Jo Lechowicz, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 9378–9379.

https://doi.org/10.1182/blood-2022-170360

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy

Danielle F Soberman, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim, Daniel J. Landsburg

Blood (2022) 140 (Supplement 1): 9514–9515.

https://doi.org/10.1182/blood-2022-165086

Published: 2022

Journal Articles

The NPM1 - TYK2 Chimeric Fusion Promotes Activation of STAT Family Signaling, Skewing Towards Tfh Functional Subset Differentiation and Mature T-Cell Lymphomagenesis

Huang-Chang Liang, Richa Kapoor, Ozlem Onder, Kevin Dennis, Megan S. Lim, Kojo S.J. Elenitoba-Johnson

Blood (2022) 140 (Supplement 1): 9281–9282.

https://doi.org/10.1182/blood-2022-169494

Published: 2022

Journal Articles

The Role of ARID1a in T Cell Differentiation & Lymphomagenesis

Richa Kapoor, Kaiyu Ma, Faith Key, Huang-Chang Liang, Xiao Zhang, Megan S. Lim, Kojo S.J. Elenitoba-Johnson

Blood (2022) 140 (Supplement 1): 9310–9311.

https://doi.org/10.1182/blood-2022-170797

Published: 2022

Journal Articles

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults

Ana C. Xavier, Lauren Harrison, Rodney R. Miles, Stephan Voss, Megan S. Lim, Mitchell S. Cairo

Blood (2022) 140 (Supplement 1): 12029–12030.

https://doi.org/10.1182/blood-2022-160045

Published: 2022

Journal Articles

A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 711.

https://doi.org/10.1182/blood-2021-151245

Published: 2021

Journal Articles

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Blood (2021) 138 (Supplement 1): 805.

https://doi.org/10.1182/blood-2021-148663

Published: 2021

Journal Articles

Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease

Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2021-153397

Published: 2021

Journal Articles

Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease

Sheila K Pierson, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2021-153840

Published: 2021

Journal Articles

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK + ALCL: results of COG trial ANHL12P1

Eric J. Lowe, Anne F. Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig, Donald A. Barkauskas, Rui Wu, Sarah Alexander, Catherine M. Bollard

Blood (2021) 137 (26): 3595–3603.

https://doi.org/10.1182/blood.2020009806

Published: 2021

Includes: Supplemental data

Journal Articles

A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

Jie Wang, MDMS, Katarzyna Urbanska, PhD, Prannda Sharma, Mathilde Poussin, Reza Nejati, MD, Lauren Shaw, Megan S. Lim, MD PhD, Stephen J. Schuster, MD, Daniel Powell, Jr., PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142010

Published: 2020

Journal Articles

Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL

Rui Wu, MD PhD, Elena Ivan, MD, Anagh Anant Sahasrabuddhe, PhDMSc,BSc, Timothy Shaw, PhD, Charles G. Mullighan, MBBS, MD, Vasiliki Leventaki, Kojo S. J. Elenitoba-Johnson, MD, Megan S. Lim, MD PhD

Blood (2019) 134 (Supplement_1): 1510.

https://doi.org/10.1182/blood-2019-127453

Published: 2019

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

PMBCL: a molecular diagnosis?

Megan S. Lim

Blood (2018) 132 (22): 2319–2320.

https://doi.org/10.1182/blood-2018-10-878660

Published: 2018

NARROW

NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy

The NPM1 - TYK2 Chimeric Fusion Promotes Activation of STAT Family Signaling, Skewing Towards Tfh Functional Subset Differentiation and Mature T-Cell Lymphomagenesis

The Role of ARID1a in T Cell Differentiation & Lymphomagenesis

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults

A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease

Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK + ALCL: results of COG trial ANHL12P1

A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

PMBCL: a molecular diagnosis?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only